(UroToday.com) At the 2026 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Laurence Albiges and colleagues presented the study design of LUTEON, an ongoing, randomized phase III ...

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...

Radical cystectomy remains a major operation even at experienced centers and with robotic surgical techniques. Data from the ...

(UroToday.com) The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alexander Decruyenaere discussing an ancillary study of the ProBio trial assessing the ...

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed ...

The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Mehdi Bsilat discussing the impact ...

Most CTC-evaluable patients in TALAPRO-2 had relatively low CTC burden at baseline, with 81.5% having <5 CTCs/7.5 mL and 65.3 ...

The 2026 ESMO annual meeting featured a rapid oral session and a discussant presentation by Dr. Alison Reid discussing three ...

Adaptive Dosing of Actinium-225 Alpitatug Satetraxetan, a KLK2-Targeted Radioligand Therapy, in mCRPC - Pedro Barata Circulating Tumor DNA Alterations and Resistance to Lutetium-177 PSMA-617 in ...

(UroToday.com) The 2026 European Society of Medical Oncology (ESMO) Annual Congress held the session: Genitourinary tumour, ...

A total of 25 patients who received ≥2 cycles of toripalimab combined with TIP chemotherapy were enrolled. The objective response rate was 84.0%, with 2 patients achieving complete response and 19 ...

This analysis included 58 patients treated with gemcitabine intravesical system monotherapy in the SunRISe-1 cohort who had ...